《異動》同源康醫藥(02410.HK)大成交炒高36% 上月初完成配股淨籌近1.55億元
內地臨床階段生物製藥公司同源康醫藥-B(02410.HK)今早(16日)高開3.16%報15.98元,早段曾飆45.6%高見22.56元創約一個半月高。現報21.08元,升36.09%,成交激增至7,003.5萬股(上日全日成交757萬股),涉資13億元。
該股去年8月下旬上市,上市價12.1元。其今年8月初完成配售新H股,以每股17.01元的配售價成功配售合共923萬股,相當於經擴大股本約2.43%,淨籌近1.55億元。該股上半年未錄得收入,虧損收窄至1.12億元人民幣(下同),上年同期蝕2.19億元;每股虧損0.3元。不派息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.